Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


18.08.2025

1 BMC Cancer
1 BMC Urol
2 Cancer
2 Cancer Lett
3 Clin Cancer Res
1 Clin Imaging
1 Clin Med Insights Oncol
3 Eur Urol
1 Int J Cancer
1 Int J Urol
1 J Magn Reson Imaging
2 J Natl Cancer Inst
2 J Urol
1 Nat Rev Urol
1 PLoS One
3 Prostate


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Cancer

  1. CUI F, Zhang Y, Tang X, Gong D, et al
    Weight gain or loss after diagnosis and survival outcomes in prostate cancer: a meta-analysis.
    BMC Cancer. 2025;25:1286.
    PubMed         Abstract available


    BMC Urol

  2. XIONG J, Liu Y, Qiao X, Ai G, et al
    A novel composite index of PSA and periprostatic adipose tissue quantification for enhancing high-grade prostate cancer prediction.
    BMC Urol. 2025;25:199.
    PubMed         Abstract available


    Cancer

  3. SANDERS J, Levell C, Brand LJ, Dahut WL, et al
    Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative.
    Cancer. 2025;131:e70010.
    PubMed         Abstract available

  4. SAEED F, Berchuck JE, Bilen MA, Gandhi JS, et al
    Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches.
    Cancer. 2025;131:e70037.
    PubMed         Abstract available


    Cancer Lett

  5. GU R, Janknecht J, Oh S, Jiang H, et al
    Anti-tumor activity of CDYL2b in prostate cancer.
    Cancer Lett. 2025 Aug 12:217987. doi: 10.1016/j.canlet.2025.217987.
    PubMed         Abstract available

  6. THARIAN L, Verma S, Feinberg D, Parameswaran R, et al
    Chimeric Antigen Receptor-Engineered (CAR)-T Cell Therapy for Metastatic Prostate Cancer.
    Cancer Lett. 2025 Aug 12:217986. doi: 10.1016/j.canlet.2025.217986.
    PubMed         Abstract available


    Clin Cancer Res

  7. OWIREDU J, Ersoy-Fazlioglu B, Poluben L, Calagua C, et al
    Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancer.
    Clin Cancer Res. 2025 Aug 12. doi: 10.1158/1078-0432.CCR-22-3683.
    PubMed         Abstract available

  8. NAYAK S, Norris JD, Ammirante M, Rychak E, et al
    Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0471.
    PubMed         Abstract available

  9. JIAO J, Ma S, Wu P, Song X, et al
    Transrectal Ultrasound-Guided Prostate Biopsy With and Without PSMA PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0320.
    PubMed         Abstract available


    Clin Imaging

  10. SIMON BD, Harmon SA, Merriman KM, Tetreault J, et al
    A multimodal automated deep learning-based model for predicting biochemical recurrence of prostate cancer following prostatectomy from baseline MRI, Presurgical clinical covariates.
    Clin Imaging. 2025;126:110579.
    PubMed         Abstract available


    Clin Med Insights Oncol

  11. HILIBRAND AS, Tuac Y, Argun O, Breneman CM, et al
    Age-Specific Impact of Cribriform Pattern in Prostate Cancer Following Radical Prostatectomy.
    Clin Med Insights Oncol. 2025;19:11795549251363324.
    PubMed         Abstract available


    Eur Urol

  12. MONTORSI F, Barletta F, Gandaglia G, Briganti A, et al
    Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial.
    Eur Urol. 2025 Aug 11:S0302-2838(25)00400-2. doi: 10.1016/j.eururo.2025.
    PubMed        

  13. FAHRNER M, Zamboglou C, Spohn SKB, Oerther B, et al
    Advancing Radioproteomics: Integration of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Localized Proteomic Profiling in Prostate Cancer.
    Eur Urol. 2025 Aug 11:S0302-2838(25)00393-8. doi: 10.1016/j.eururo.2025.
    PubMed        

  14. SANTIAGO I, Rivas JG
    Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.
    Eur Urol. 2025 Aug 13:S0302-2838(25)00440-3. doi: 10.1016/j.eururo.2025.
    PubMed        


    Int J Cancer

  15. HAN Y, Li C, Sun J, Wu G, et al
    Comments on "CTHRC1 promotes bone metastasis in prostate cancer".
    Int J Cancer. 2025 Aug 8. doi: 10.1002/ijc.70081.
    PubMed        


    Int J Urol

  16. ARAI S
    Editorial Comment on Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Aug 10. doi: 10.1111/iju.70201.
    PubMed        


    J Magn Reson Imaging

  17. ESENGUR OT, Stecko H, Stevenson E, Turkbey B, et al
    Toward a Refined PI-RADS: The Feasibility and Limitations of More Informative Metrics in Reviewing MRI Scans.
    J Magn Reson Imaging. 2025 Mar 26. doi: 10.1002/jmri.29754.
    PubMed         Abstract available


    J Natl Cancer Inst

  18. QIAN Z, Korn S, Zurl H, Stelzl D, et al
    Active surveillance for low-risk prostate cancer: long-term utilization and outcomes among black men.
    J Natl Cancer Inst. 2025 Aug 14:djaf224. doi: 10.1093.
    PubMed         Abstract available

  19. MAKAROV DV, Thomas JK, Ciprut S, Rivera AJ, et al
    Prostate Cancer Imaging Stewardship: a multi-modal, physician-centered intervention for guideline-concordant imaging.
    J Natl Cancer Inst. 2025 Aug 11:djaf210. doi: 10.1093.
    PubMed         Abstract available


    J Urol

  20. JOYCE DD, Siemens DR
    Shared Decision-Making in Prostate Cancer Management: Easy to Say, Hard to Measure.
    J Urol. 2025 Aug 14:101097JU0000000000004698. doi: 10.1097/JU.0000000000004698.
    PubMed        

  21. VICKERS A, Touijer K
    Letter: Pelvic Lymph Node Dissection in Prostate Cancer: Is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection vs Radical Prostatectomy Only.
    J Urol. 2025 Aug 12:101097JU0000000000004696. doi: 10.1097/JU.0000000000004696.
    PubMed        


    Nat Rev Urol

  22. CONTEDUCA V, Beltran H
    State of the art - biomarkers in advanced prostate cancer.
    Nat Rev Urol. 2025 Aug 12. doi: 10.1038/s41585-025-01080.
    PubMed        


    PLoS One

  23. HAMADA M, Nakata E, Nakahara R, Sugihara S, et al
    Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases.
    PLoS One. 2025;20:e0328792.
    PubMed         Abstract available


    Prostate

  24. BERTINI A, Stephens A, Finocchiaro A, Vigano S, et al
    Mortality and Additional Treatment Rates in Pathologically High-Risk Prostate Cancer With Prostate-Specific Antigen Persistence at Robot-Assisted Radical Prostatectomy: Long-Term Report From Single Tertiary Referral Center.
    Prostate. 2025 Aug 10. doi: 10.1002/pros.70031.
    PubMed         Abstract available


  25. Erratum to "Inhibition of Signaling Downstream of Beta-2 Adrenoceptor by Propranolol in Prostate Cancer Cells".
    Prostate. 2025 Aug 13. doi: 10.1002/pros.70033.
    PubMed        

  26. YILMAZ AB
    Letter to the Editor: "Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms".
    Prostate. 2025 Aug 13. doi: 10.1002/pros.70012.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.